Anagrelide

DRUG6 trials

Sponsors

Shire, AOP Orphan Pharmaceuticals AG, French Innovative Leukemia Organisation, Incyte Corporation, PharmaEssentia

Conditions

Essential ThrombocythaemiaEssential ThrombocythemiaMPN (Myeloproliferative Neoplasms)Thrombocythemia, Hemorrhagic

Phase 2

The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line

TerminatedNCT02962388

French Innovative Leukemia OrganisationEssential Thrombocythemia

Start: 2017-01-03End: 2021-06-28Updated: 2021-06-29

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

TerminatedNCT03123588

Incyte CorporationMPN (Myeloproliferative Neoplasms)

Start: 2017-11-14End: 2020-08-03Updated: 2021-11-19

Phase 3

Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia

CompletedNCT01065038

AOP Orphan Pharmaceuticals AGEssential Thrombocythaemia

Start: 2002-09-30Updated: 2010-10-06

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

Active, not recruitingNCT04285086

PharmaEssentiaEssential Thrombocythemia

Start: 2020-08-25End: 2029-08-31Updated: 2025-08-13

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

RecruitingNCT06079879

Merck Sharp & Dohme LLCEssential Thrombocythemia

Start: 2023-12-31End: 2028-08-18Target: 340Updated: 2026-03-13

Phase 4

A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients

CompletedNCT00202644

ShireThrombocythemia, Hemorrhagic

Start: 2006-01-13End: 2015-12-15Updated: 2021-06-02

Related Papers

Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study.

2025-11-01

Ropeginterferon alfa-2b versus anagrelide for the treatment of essential thrombocythemia: Topline results of the phase 3 SURPASS-ET trial.

Journal of Clinical Oncology2025-05-283 citations

Phase 3 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in patients with essential thrombocythemia (ET).

Journal of Clinical Oncology2024-06-01

ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.

2024-03-0411 citations

SURPASS-ET: phase III Study of Ropeginterferon Alfa-2b versus Anagrelide as Second-Line Therapy in Essential Thrombocythemia

Future Oncology2022-08-0438 citations

Surpass-ET Trial: A Phase 3, Open-Label, Multicenter, Randomized, Active-Controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 Vs Anagrelide As Second Line Therapy for Essential Thrombocythemia

Blood2021-11-051 citations

Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia.

2020-10-295 citations

Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study

Leukemia Research2018-10-1116 citations

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.

2013-01-11220 citations